Literature DB >> 7448729

Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval.

M E Lippman, J C Allegra.   

Abstract

The usefulness of estrogen receptor (ER) analyses was assessed in a variety of clinical situations. The predictive accuracy of the test is substantially increased by quantification. ER analyses accurately predict objective responses to endocrine therapy independently of other clinical prognostic criteria. In addition, ER positivity is associated with a decreased response rate to cytotoxic chemotherapy in patients with metastatic breast cancer. Finally, the presence of ER is positively associated with a prolonged disease-free interval independent of menopausal status, tumor size, and axillary lymph node involvement.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7448729     DOI: 10.1002/1097-0142(19801215)46:12+<2829::aid-cncr2820461419>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  32 in total

1.  Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer. Ten year results of the Naples (GUN) Study.

Authors:  S De Placido; C Gallo; A Marinelli; F Perrone; C Pagliarulo; G Petrella; G Delrio; M D'Istria; L Del Mastro; A R Bianco
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

Review 2.  Endocrine therapy of metastatic breast cancer.

Authors:  A Manni
Journal:  J Endocrinol Invest       Date:  1989-05       Impact factor: 4.256

3.  Comparison between a biochemical and a histochemical method for the detection of oestrogen receptor in breast carcinoma.

Authors:  R T McMahon; C E Connolly
Journal:  Ir J Med Sci       Date:  1985-05       Impact factor: 1.568

4.  Genomic DNA analysis of the estrogen receptor gene in breast cancer.

Authors:  F F Parl; D R Cavener; W D Dupont
Journal:  Breast Cancer Res Treat       Date:  1989-10       Impact factor: 4.872

5.  Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer.

Authors:  Xin Pan; Tao Zhou; Yan-Hong Tai; Chenguang Wang; Jie Zhao; Yuan Cao; Yuan Chen; Pei-Jing Zhang; Ming Yu; Cheng Zhen; Rui Mu; Zhao-Fang Bai; Hui-Yan Li; Ai-Ling Li; Bing Liang; Zhao Jian; Wei-Na Zhang; Jiang-Hong Man; Yan-Fei Gao; Wei-Li Gong; Li-Xin Wei; Xue-Min Zhang
Journal:  Nat Med       Date:  2011-05-15       Impact factor: 53.440

6.  Localization of the human progesterone receptor gene to chromosome 11q22-q23.

Authors:  M F Rousseau-Merck; M Misrahi; H Loosfelt; E Milgrom; R Berger
Journal:  Hum Genet       Date:  1987-11       Impact factor: 4.132

Review 7.  Postmenopausal hormone replacement therapy: effects on normal mammary gland in humans and in a mouse postmenopausal model.

Authors:  Sandra Z Haslam; Janet R Osuch; A M Raafat; L J Hofseth
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-01       Impact factor: 2.673

8.  Simultaneous and sequential determinations of steroid hormone receptors in human breast cancer. Influence of intervening therapy.

Authors:  R Jakesz; C Dittrich; J Hanusch; R Kolb; R Lenzhofer; K Moser; H Rainer; G Reiner; M Schemper; J Spona
Journal:  Ann Surg       Date:  1985-03       Impact factor: 12.969

Review 9.  Tracking progesterone receptor-mediated actions in breast cancer.

Authors:  Todd P Knutson; Carol A Lange
Journal:  Pharmacol Ther       Date:  2013-11-26       Impact factor: 12.310

10.  Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months.

Authors:  Ou Huang; Canming Chen; Jiayi Wu; Shujie Chen; Xiaosong Chen; Guangyu Liu; Zhen Hu; Jingsong Lu; Jiong Wu; Zhimin Shao; Zhenzhou Shen; Kunwei Shen
Journal:  BMC Cancer       Date:  2009-10-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.